News
Ipsen and its fellow French partner Genfit are competing with Intercept and Advanz’s Ocaliva, which was approved in 2016 and ...
A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...
1d
Zacks Investment Research on MSNHere's Why Gilead Sciences (GILD) is a Strong Value StockIt doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.
6d
Screen Rant on MSNHow The Handmaid's Tale Sequel Show Approaches Gilead Differently Explained By EPsExclusive: Bruce Miller and Warren Littlefield explain how The Handmaid's Tale's sequel show, The Testaments, approaches ...
4d
US Weekly on MSNWhat to Know About ‘The Handmaid’s Tale’ Spinoff ‘The Testaments’: Returning Cast Members and MoreHulu's spinoff of 'The Handmaid's Tale' titled 'The Testaments' comes after the original show's sixth and final season ...
The Handmaid’s Tale Season 6 finale is just a few weeks away, but fans hoping for a neatly wrapped story to June Osbourne and ...
Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...
As the final season of "The Handmaid's Tale" begins today, we're taking a look back on everything to know about the hit Hulu ...
On The Handmaid's Tale Season 6 Episode 4 Joseph gets a promotion for his reforms while the resistance plans a major assault ...
"It's not about a relationship she chose, like with Fred," Bruce Miller says, explaining why writers chose to introduce the ...
Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results